Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non-subtype B HIV-1-infected Patients in South East Asia

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2014 Jan 14

PMID 24413039

Citations 21

Authors

Praphan Phanuphak

Sunee Sirivichayakul

Awachana Jiamsakul

Somnuek Sungkanuparph

Nagalingeswaran Kumarasamy

Man Po Lee

Thira Sirisanthana

Pacharee Kantipong

Christopher Lee

Adeeba Kamarulzaman

Mahiran Mustafa

Rossana Ditangco

Tuti Merati

Winai Ratanasuwan

Thida Singtoroj

Rami Kantor

Affiliations

Soon will be listed here.

Abstract

Background: We compared treatment outcomes of transmitted drug resistance (TDR) in patients on fully or partially sensitive drug regimens.

Methods: Factors associated with survival and failure were analyzed using Cox proportional hazards and discrete time conditional logistic models.

Results: TDR, found in 60 (4.1%) of 1471 Asian treatment-naive patients, was one of the significant predictors of failure. Patients with TDR to >1 drug in their regimen were >3 times as likely to fail compared to no TDR.

Conclusions: TDR was associated with failure in the context of non-fully sensitive regimens. Efforts are needed to incorporate resistance testing into national treatment programs.

Citing Articles

Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.

Bello G, Kagoli M, Chipeta S, Auld A, Chang J, DeVos J Antivir Ther. 2022; 27(4):13596535221121225.

PMID: 35976773 PMC: 9555317. DOI: 10.1177/13596535221121225.

Patterns and prognosis of holding regimens for people living with HIV in Asian countries.

Kim J, Jiamsakul A, Kiertiburanakul S, Huy B, Khusuwan S, Kumarasamy N PLoS One. 2022; 17(3):e0264157.

PMID: 35353840 PMC: 8967045. DOI: 10.1371/journal.pone.0264157.

Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.

Gao P, Yu F, Yang X, Li D, Shi Y, Wang Y Curr HIV Res. 2021; 20(1):32-41.

PMID: 34515004 PMC: 9127726. DOI: 10.2174/1570162X19666210910144433.

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis.

Bertagnolio S, Hermans L, Jordan M, Avila-Rios S, Iwuji C, Derache A J Infect Dis. 2020; 224(3):377-388.

PMID: 33202025 PMC: 8328216. DOI: 10.1093/infdis/jiaa683.

Evaluation of Selected Outcomes of Combination Antiretroviral Therapy: Yemen Cohort Retrospective Descriptive Studies.

Nabih M, Wan Puteh S, Nur A Sci Rep. 2019; 9(1):19923.

PMID: 31882645 PMC: 6934668. DOI: 10.1038/s41598-019-56314-0.

References

Gupta R, Jordan M, Sultan B, Hill A, Davis D, Gregson J . Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012; 380(9849):1250-8. PMC: 3790969. DOI: 10.1016/S0140-6736(12)61038-1. View

Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R . TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009; 159(2):185-93. PMC: 2863146. DOI: 10.1016/j.jviromet.2009.03.016. View

Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L . Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008; 13 Suppl 2:101-7. View

Kuritzkes D, Lalama C, Ribaudo H, Marcial M, Meyer 3rd W, Shikuma C . Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008; 197(6):867-70. DOI: 10.1086/528802. View

Sohn A, Srikantiah P, Sungkanuparph S, Zhang F . Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS. 2012; 8(1):27-33. DOI: 10.1097/COH.0b013e32835b804f. View

Weinstein M, Goldie S, Losina E, Cohen C, Baxter J, Zhang H . Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001; 134(6):440-50. DOI: 10.7326/0003-4819-134-6-200103200-00008. View

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein M, Morand-Joubert L . The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007; 8(7):439-50. PMC: 3073616. DOI: 10.1111/j.1468-1293.2007.00491.x. View

Truong H, Grant R, McFarland W, Kellogg T, Kent C, Louie B . Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS. 2006; 20(17):2193-7. DOI: 10.1097/01.aids.0000252059.85236.af. View

10.

Yanik E, Napravnik S, Hurt C, Dennis A, Quinlivan E, Sebastian J . Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr. 2012; 61(2):258-62. PMC: 3458150. DOI: 10.1097/QAI.0b013e3182618f05. View

11.

Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A . Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006; 41(4):439-46. DOI: 10.1097/01.qai.0000219290.49152.6a. View

12.

Hamers R, Wallis C, Kityo C, Siwale M, Mandaliya K, Conradie F . HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011; 11(10):750-9. DOI: 10.1016/S1473-3099(11)70149-9. View

13.

Wittkop L, Gunthard H, de Wolf F, Dunn D, Cozzi-Lepri A, De Luca A . Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5):363-71. DOI: 10.1016/S1473-3099(11)70032-9. View

14.

Somi G, Kibuka T, Diallo K, Tuhuma T, Bennett D, Yang C . Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther. 2008; 13 Suppl 2:77-82. View

15.

Hingankar N, Thorat S, Deshpande A, Rajasekaran S, Chandrasekar C, Kumar S . Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis. 2012; 54 Suppl 4:S348-54. PMC: 3338312. DOI: 10.1093/cid/cis005. View

16.

Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P . Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS. 2007; 21(16):2223-9. DOI: 10.1097/QAD.0b013e3282f0b685. View

17.

Bennett D, Camacho R, Otelea D, Kuritzkes D, Fleury H, Kiuchi M . Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3):e4724. PMC: 2648874. DOI: 10.1371/journal.pone.0004724. View

18.

Little S, Holte S, Routy J, Daar E, Markowitz M, Collier A . Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347(6):385-94. DOI: 10.1056/NEJMoa013552. View

19.

de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C . An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005; 21(19):3797-800. DOI: 10.1093/bioinformatics/bti607. View

20.

Monge S, Guillot V, Alvarez M, Pena A, Viciana P, Garcia-Bujalance S . Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. Clin Microbiol Infect. 2012; 18(11):E485-90. DOI: 10.1111/1469-0691.12011. View